Changeflow GovPing Pharma & Drug Safety Patent EP4626864A1: Diamide Activators by Prote...
Routine Notice Added Final

Patent EP4626864A1: Diamide Activators by Protego Biopharma

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published March 11th, 2026
Detected March 26th, 2026
Email

Summary

The European Patent Office has published patent application EP4626864A1, titled 'Diamide Activators', filed by Protego Biopharma, Inc. The patent covers novel chemical compounds intended for use as IRE1/XBP1s activators.

What changed

The European Patent Office (EPO) has published patent application EP4626864A1, which details "LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS" developed by Protego Biopharma, Inc. The application includes extensive International Patent Classification (IPC) codes related to organic chemistry and pharmaceutical compositions, indicating a focus on novel chemical entities and their potential therapeutic applications.

This publication represents the granting of a patent for specific chemical compounds and their uses. While it does not impose direct compliance obligations on regulated entities in the same way as a rule or guidance, it establishes intellectual property rights for Protego Biopharma. Companies operating in the pharmaceutical sector, particularly those involved in drug discovery and development related to IRE1/XBP1 signaling pathways, should be aware of this patent to avoid potential infringement and to inform their own research and development strategies.

Source document (simplified)

← EPO Patent Bulletin

LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS

Publication EP4626864A1 Kind: A1 Mar 11, 2026

Applicants

Protego Biopharma, Inc.

Inventors

LABAUDINIERE, Richard F., TAIT, Bradley Dean, QIU, Huang, PETRASSI, Hank Michael James, QIN, Bo

IPC Classifications

C07D 231/40 20060101AFI20250623BHEP C07D 285/08 20060101ALI20250623BHEP C07D 401/12 20060101ALI20250623BHEP C07D 401/14 20060101ALI20250623BHEP C07D 403/12 20060101ALI20250623BHEP C07D 405/12 20060101ALI20250623BHEP C07D 405/14 20060101ALI20250623BHEP C07D 471/04 20060101ALI20250623BHEP C07D 487/04 20060101ALI20250623BHEP C07D 491/056 20060101ALI20250623BHEP A61K 31/415 20060101ALI20250623BHEP A61K 31/433 20060101ALI20250623BHEP A61K 31/4355 20060101ALI20250623BHEP A61K 31/437 20060101ALI20250623BHEP A61K 31/4439 20060101ALI20250623BHEP A61K 31/497 20060101ALI20250623BHEP A61K 31/506 20060101ALI20250623BHEP A61P 1/00 20060101ALI20250623BHEP A61P 1/16 20060101ALI20250623BHEP A61P 3/10 20060101ALI20250623BHEP A61P 9/00 20060101ALI20250623BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Applicants Inventors IPC Classifications Designated States

Classification

Agency
EPO
Published
March 11th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4626864A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Chemical Synthesis
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.